Core Viewpoint - Johnson & Johnson announced the approval of Daratumumab subcutaneous injection (DVRd) for the treatment of newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation, providing a significant new treatment option that improves prognosis [1] Group 1: Treatment Approval and Efficacy - The approval is based on the results of the Phase III PERSEUS study, which compared two treatment regimens: DVRd and VRd [1] - The study showed that the DVRd regimen reduced the risk of disease progression or death by 58% compared to the VRd regimen (HR = 0.42; 95% CI: 0.30–0.59; p<0.0001) [1] - The overall minimal residual disease (MRD) negative rate for the DVRd group was 75.2%, significantly higher than the 47.5% in the VRd group (p < 0.0001) [1] - The percentage of patients achieving complete response or better was 87.9% in the DVRd group, compared to 70.1% in the VRd group (p < 0.0001) [1] - The proportion of patients with sustained MRD negativity for ≥12 months was 64.8% in the DVRd group, compared to 29.7% in the VRd group [1] Group 2: Clinical Implications and Commitment - The new treatment regimen is expected to provide significant clinical benefits for newly diagnosed multiple myeloma patients, reinforcing the company's commitment to delivering transformative therapies [1] - The company aims to improve treatment outcomes and establish new treatment standards for multiple myeloma patients, focusing on functional cure and comprehensive patient health management [1] Group 3: Safety Profile - The overall safety profile of the DVRd regimen is consistent with the known safety characteristics of Daratumumab and the VRd regimen [2] - Common hematological adverse reactions (≥20% incidence) include neutropenia, thrombocytopenia, and anemia [2] - Common non-hematological adverse reactions include peripheral neuropathy, fatigue, peripheral edema, fever, upper respiratory infections, COVID-19, constipation, diarrhea, back pain, insomnia, fatigue, and rash [2]